The Food and Drug Administration on Tuesday granted emergency use authorization to the updated COVID-19 vaccine from Novavax, marking the third new coronavirus shot that will be made available to the public ahead of the winter and the only not produced with messenger RNA technology.
FDA authorized the shot for people ages 12 and older just weeks after shots from Moderna and Pfizer rolled out.
“Today’s authorization provides an additional COVID-19 vaccine option that meets the FDA’s standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization,” Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement.
Some individuals are skeptical of the new technology, instead opting for Novavax’s more traditional use of protein-based technology.
“In the coming days, individuals in the U.S. can go to major pharmacies, physicians’ offices, clinics and various government entities to receive an updated Novavax vaccine.”
Persons:
“, ” Peter Marks, ”, John Jacobs
Organizations:
Drug Administration, FDA, Moderna, Pfizer, FDA’s, Biologics, Research, Health, Covid
Locations:
U.S